Population pharmacokinetic/pharmacodynamic assessment of imipenem/cilastatin/relebactam in patients with hospital‐acquired/ventilator‐associated bacterial pneumonia

• Үндсэн зохиолчид: Munjal Patel (Зохиогч), Francesco Bellanti (Зохиогч), Naveen M. Daryani (Зохиогч), Nadia Noormohamed (Зохиогч), David W. Hilbert (Зохиогч), Katherine Young (Зохиогч), Pooja Kulkarni (Зохиогч), William Copalu (Зохиогч), Ferdous Gheyas (Зохиогч), Matthew L. Rizk (Зохиогч)
• Формат: Ном
• Хэвлэсэн: Wiley, 2022-02-01T00:00:00Z.
• Нөхцлүүд: article
• Онлайн хандалт: Connect to this object online.

Abstract In the phase III RESTORE‐IMI 2 study (ClinicalTrials.gov: NCT02493764), the combination antibacterial agent imipenem/cilastatin/relebactam (IMI/REL) demonstrated noninferiority to piperacillin/tazobactam for the end points of all‐cause mortality at day 28 and favorable clinical response at...